Renaissance Technologies LLC Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Renaissance Technologies LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 60,536 shares of the medical equipment provider’s stock, valued at approximately $5,474,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Main Management ETF Advisors LLC lifted its position in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after buying an additional 112 shares in the last quarter. Citizens National Bank Trust Department grew its stake in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares during the period. LOM Asset Management Ltd increased its position in shares of Zimmer Biomet by 21.5% in the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 147 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of Zimmer Biomet by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after acquiring an additional 152 shares during the period. Finally, TD Private Client Wealth LLC raised its stake in shares of Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $98.08 on Thursday. The firm has a fifty day simple moving average of $89.61 and a 200-day simple moving average of $90.02. The company has a market capitalization of $18.98 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 2.82 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $2.07 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Activity

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.28% of the company’s stock.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Quarterly results exceeded expectations. Zimmer Biomet reported second-quarter adjusted earnings of $2.07 per share, above the $2.01 analyst consensus, while sales of $2.177 billion topped the $2.13 billion estimate. Revenue increased 4.8% year over year, or 4.0% on an organic constant-currency basis. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 outlook. The company now expects adjusted EPS of $8.47–$8.59, compared with the prior consensus estimate of approximately $8.48, and full-year revenue of about $8.6 billion versus Wall Street’s $8.5 billion expectation. The improved outlook was a key catalyst for the favorable investor reaction. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Reported profitability improved. GAAP diluted EPS rose 33.8% to $1.03, despite adjusted EPS remaining unchanged from the prior-year quarter, indicating benefits from items below the adjusted earnings line. Zimmer Biomet Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Growth was steady rather than accelerating. Adjusted EPS of $2.07 matched the year-ago result, and organic constant-currency sales growth was 4.0%. Investors will likely focus on whether new products, procedure volumes and commercial initiatives can sustain or improve that pace. Zimmer Biomet Q2 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted margins faced pressure. The earnings beat and higher outlook came despite weaker adjusted-margin performance, leaving profitability and cost control as ongoing risks to the stock’s valuation. ZBH Q2 Earnings Beat, 2026 View Raised

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price target for the company. BMO Capital Markets began coverage on Zimmer Biomet in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 price objective on the stock. Zacks Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $102.00.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.